[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337181-105":59,"doc-detail-337181-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","systematic-pan-cancer-analysis-identifies-zbtb11-as-a-potential-pan-cancer-biomarker-and-immunotherapy-target","Systematic Pan-Cancer Analysis Identifies ZBTB11 as a Potential Pan-Cancer Biomarker and Immunotherapy Target","","ZBTB11 is a putative transcription factor with an N-terminal BTB domain and C-terminal zinc finger motifs, and its role across cancer types is not fully understood. Expression, prognostic associations, genetic alterations, and DNA promoter methylation of ZBTB11 were assessed across tumor types using public databases, alongside construction of a competing lncRNA-miRNA network. Results show aberrant ZBTB11 expression, stage-dependent variability, prognostic value in multiple cancers, links to immune infiltration, single-cell implicated regulation of apoptosis, DNA damage, and angiogenesis, and correlation with drug sensitivity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/systematic-pan-cancer-analysis-identifies-zbtb11-as-a-potential-pan-cancer-biomarker-and-immunotherapy-target/337181/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/systematic-pan-cancer-analysis-identifies-zbtb11-as-a-potential-pan-cancer-biomarker-and-immunotherapy-target/337181.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is ZBTB11 and why was it studied in multiple cancer types?","Question",{"text":112,"@type":113},"ZBTB11 is a transcription factor containing an N-terminal BTB domain and C-terminal zinc finger motifs. Studies suggest it may contribute to tumorigenesis, but its biological significance across different cancers was unclear.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ZBTB11 analyzed across tumor types?",{"text":117,"@type":113},"ZBTB11 expression, prognostic value, genetic mutation status, and DNA promoter methylation were evaluated using multiple online databases. A competing lncRNA-miRNA network was also constructed, and interactions involving chemicals and genes were examined.",{"name":119,"@type":110,"acceptedAnswer":120},"What key findings support ZBTB11 as a potential biomarker and immunotherapy target?",{"text":121,"@type":113},"ZBTB11 showed aberrant expression across many tumors, with stage-dependent variation and prognostic associations in multiple cancers. It correlated with immune cell infiltration and immunomodulator markers, and single-cell sequencing suggested roles in apoptosis, DNA damage, and angiogenesis, along with links to drug sensitivity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337181,1790825481,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Analysis  \nSystematic pan‑cancer analysis identifies ZBTB11 as a potential pan‑cancer biomarker and immunotherapy target in multiple tumor types  \nPeiyi Xu1 · Qiuyan Zhang1 · Jing Zhai1 · Pu Chen1 · Xueting Deng1 · Lin Miao1 · Xiuhua Zhang1  \nReceived: 13 June 2024 / Accepted: 11 December 2024  \n© The Author(s) 2024 OPEN  \nAbstract  \nBackground ZBTB11 is a putative transcription factor with an N-terminal BTB domain and tandem C-terminal zinc finger motifs. Recent studies have suggested a potential role for ZBTB11 in tumorigenesis. However, the biological significance of ZBTB11 in different cancer types remains uncertain.  \nMethods The expression levels, prognostic values, genetic mutations, and DNA promoter methylation of ZBTB11 across tumor types were explored via various online websites and databases, including TIMER2.0, GEPIA2, cBioPortal, UALCAN, GSCA, CancerSEA, and others. Additionally, a competing lncRNA-miRNA network of ZBTB11 was constructed, and its interaction with chemicals and genes was investigated.  \nResults Our findings revealed that ZBTB11 was aberrantly expressed in a multitude of tumor types and exhibited variability across various tumor stages. A survival analysis revealed that ZBTB11 predicted a poor prognosis in BRCA, KIRP, LIHC, PCPG, PRAD, SARC, UCEC, and a good prognosis in CHOL, ESCA, GBM, KIRC, and READ. We also found that the most frequent genetic alterations type of ZBTB11 was mutation, and the DNA methylation level of ZBTB11 decreased in various cancers. Furthermore, ZBTB11 expression correlated with immune cells infiltration and genetic markers of immunodulators in cancers. Moreover, the results of single-cell sequencing demonstrated that ZBTB11 could regulate several tumor biological behaviors, including apoptosis, DNA damage, and angiogenesis. A lncRNA-miRNA network regulating ZBTB11 expression in tumor development and progression was constructed. It is of particular significance that ZBTB11 demonstrated a correlation with the CTRP and GDSC drug sensitivity, and that it served as a mediator between chemicals and cancers.  \nConclusion These findings demonstrate that ZBTB11 is associated with multiple tumor types and disease prognosis. ZBTB11 may represent a potential key biomarker and therapeutic target in cancers.  \nKeywords ZBTB11 · Pan-cancer · Prognosis · Immune · Methylation · Biomarker  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-024-](https://doi.org/10.1007/s12672-024-)[ ](https://doi.org/10.1007/s12672-024-)[01697-4](01697-4.)[.](01697-4.)  \n* Xiuhua Zhang, [1129wy@sina.com](1129wy@sina.com); Peiyi Xu, [xpy19990227@163.com](xpy19990227@163.com); Qiuyan Zhang, [qiuyanzhang00@163.com](qiuyanzhang00@163.com); Jing Zhai,  \n[2573715920@qq.com](2573715920@qq.com); Pu Chen, [hgchenpu@126.com](hgchenpu@126.com); Xueting Deng, [xtdeng@njmu.edu.cn](xtdeng@njmu.edu.cn); Lin Miao, [linmiao@njmu.edu.cn |](linmiao@njmu.edu.cn |1Department)[1](linmiao@njmu.edu.cn |1Department)[Department](linmiao@njmu.edu.cn |1Department)  \n[of Gastroenterology](of Gastroenterology), Second Affiliated Hospital, Nanjing Medical University, 121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu, China.  \nDiscover Oncology  \n(2024) 15:830  \n| [https://doi.org/10.1007/s12672-024-01697-4](https://doi.org/10.1007/s12672-024-01697-4)  \nFig. 1 Differential expression of ZBTB11 in normal and tumor tissue samples. A ZBTB11 expression in pancancer tissues and adjacent nor- ▸ mal tissues by TIMER2.0 . B ZBTB11 expression levels in CHOL, DLBC, and THYM from GEPIA2( |Log2FC|> 1, P \u003C 0.01, log scale: log2 (TPM + 1), Jitter Size: 0.4) . C The ZBTB11 expression profile across all tumor samples and paired normal tissues via GEPIA2 portal (Acute Myeloid Leukemia with the highest expression is shown in red label) . D Immunohistochemistry images of ZBTB11 protein in tumor tissues including lung cancer, ovarian cancer, pancreatic cancer, and urothelial cancer, ","cbCaii3BBdLxWoAz","https://ap.wps.com/l/cbCaii3BBdLxWoAz","pdf",9318950,23,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is ZBTB11 and why was it studied in multiple cancer types?\",\"answer\":\"ZBTB11 is a transcription factor containing an N-terminal BTB domain and C-terminal zinc finger motifs. Studies suggest it may contribute to tumorigenesis, but its biological significance across different cancers was unclear.\"},{\"question\":\"How was ZBTB11 analyzed across tumor types?\",\"answer\":\"ZBTB11 expression, prognostic value, genetic mutation status, and DNA promoter methylation were evaluated using multiple online databases. A competing lncRNA-miRNA network was also constructed, and interactions involving chemicals and genes were examined.\"},{\"question\":\"What key findings support ZBTB11 as a potential biomarker and immunotherapy target?\",\"answer\":\"ZBTB11 showed aberrant expression across many tumors, with stage-dependent variation and prognostic associations in multiple cancers. It correlated with immune cell infiltration and immunomodulator markers, and single-cell sequencing suggested roles in apoptosis, DNA damage, and angiogenesis, along with links to drug sensitivity.\"}]","Systematic Pan-Cancer Analysis Identifies ZBTB11 as a Potential Pan-Cancer Biomarker and Immunotherapy Target | PDF",1790018036,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04baf3dee412159f132585fcd90ad635.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32bd8ea63fd4e98bba632e9be0310e3e.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a089502abf12dd5481e268a1d602f12d.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d662cf54f8df00315e897988062c3ad5.webp",980,1301]